Fig. 4: In vitro therapeutic efficacy of MM@BPPF. | Nature Communications

Fig. 4: In vitro therapeutic efficacy of MM@BPPF.

From: Intranasal blood-brain barrier bypass enables sequential mitochondria-targeted bioengineered nanolamellar system for ischemic stroke therapy

Fig. 4: In vitro therapeutic efficacy of MM@BPPF.

A Calcein-AM (live) and PI (dead) staining of PC12 cells subjected to OGD/R after different treatments. Normal PC12 cells were used as control, scale bar: 50 μm. B Cell viability of OGD/R-induced PC12 cells after different treatments by MTT assay. C FCM plots of Annexin V/PI-stained PC12 cells subjected to OGD/R after different treatments, and D their quantitative analysis. E TUNEL staining of PC12 cells subjected to OGD/R after different treatments, scale bar: 50 μm. The CLSM images were representative data from 3 independent experiments. F Detection of ROS levels in PC12 cells exposed to OGD/R after different treatments, scale bar: 20 μm, and G their flow cytometric quantification. The CLSM images were representative data from 3 independent experiments. H Wound healing assay of PC12 cells subjected to OGD/R after different treatments. The images were representative data from 3 independent experiments. I LDH levels in PC12 cells exposed to OGD/R after different treatments. The data represent the means ± SD, n = 3 independent experiments in (B, D, I). Statistics: one-way ANOVA with Tukey’s multiple comparison test (B, D, I), *p < 0.05, **p < 0.01, ****p < 0.0001. Source data are provided as a Source Data file.

Back to article page